Resequencing the Apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 715-720

  Evans, D ^a   Aberle, J ^a   Beil, F U ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

APOA5; Hypertriglyceridemia; Rare variants; Resequencing; Type III Hyperlipidemia

Indexed keywords

APOLIPOPROTEIN A5; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; DNA SEQUENCE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTRIGLYCERIDEMIA; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS A; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; HYPERTRIGLYCERIDEMIA; INTRONS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; TRIGLYCERIDES; UP-REGULATION;

EID: 82955203653     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.030     Document Type: Article

References (27)

1. Kathiresan S., Willer C.J., Peloso G., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
2. Teslovich T.M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
3. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
4. Cohen J.C., Kiss R.S., Pertsemlidis A., et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
5. Wang J., Cao H., Ban M.R., et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 2007, 27:2450-2455.
6. Edmondson A., Brown R.J., Kathiresan S., et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009, 119(4):1042-1050.
7. Johansen C.T., Wang J., Lanktree M.B., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010, 42:684-687.
8. Evans D., Arzer J., Aberle J., Beil F.U. Rare variants in the lipoprotein lipase gene are common in hypertriglyceridemia but rare in Type III Hyperlipidemia. Athereosclerosis 2011, 214:386-390.
9. Hubacek J.A. Apolipoprotein A5 and triglyceridemia. Focus on the effects of common variants. Clin Chem Lab Med 2005, 43:897-902.
10. Wang J., Ban M.R., Kennedy B.A., et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008, 5:730-737.
11. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
12. Dorfmeister B., Zeng W.W., Dichelberger A., Nilsson S.K., et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 2008, 28:1866-1871.
13. Charriere S., Cugnet C., Guitard M., Bernard S., et al. Modulation of phenotypic expression of APOA5 Q97X and L242P mutations. Atherosclerosis 2009, 207:150-156.
14. Mahley R.W., Huang Y., Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries and paradoxes. J Lipid Res 1999, 40:1933-1949.
15. Mahley R.W., Rall S.C. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. The metabolic and molecular bases of inherited disease 2001, 2835-2862. McGraw Hill, New York. 8th ed. Scriver (Ed.).
16. Evans D., Seedorf U., Beil F.U. Polymorphisms in the apolipoprotein A5 (APOA5) gene and Type III Hyperlipidemia. Clin Genet 2005, 68:369-372.
17. Schaefer J.R., Sattler A.M., Hackler B., et al. Hyperlipidemiain patients with apolipoprotein E2/2 phenotype: apolipoproteinA5 S19W mutation as a cofactor. Clin Chem 2004, 2214:50.
18. Henneman P., de Beer F.S., Moghaddam P.H., et al. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes. Eur J Hum Genet 2009, 17:620-628.
19. Blom D.J., O'Neill F.H., Marais A.D. Screening for dysbetalipoproteinemia by plasma cholesterol and Apolipoprotein B concentrations. Clin Chem 2005, 51:904-907.
20. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990, 31:545-548.
21. Priore Oliva C., Pisciotta L., Li Volti G., Sambataro M.P., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005, 25:411-417.
22. Sunyaev S., Ramensky V., Koch I., et al. Prediction of deleterious human alleles. Hum Mol Genet 2001, 10:591-597.
23. Oliva C.P., Carubbi F., Schaap F.G., Bertoloini S., et al. Hypertriglyceridemia and low plasma HDL in a patient with apolipoprotein A_V deficiency due to a novel mutation in the APOA5 gene. J Int Med 2008, 263:450-458.
24. Olivier M., Wang X., Cole R., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004, 83:912-923.
25. Kao J.T., Wen H.C., Chien K.L., Hsu H.C., et al. A novel genetic variant in apolipoprotein A5 is associated with hypertriglyceridemia. Hum Mol Genet 2003, 12:2533-2539.
26. Hubacek J.A., Wang W.W., Skodova Z., Adamkova V., et al. APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clin Chem Lab Med 2008, 46:773-777.
27. Marcais C., Verges B., Charriere S., Pruneta V., et al. ApoA5 Q135X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005, 115:2862-2869.